Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices

Join us for this live meeting series and interact with the presenting faculty as they discuss their perspectives on the latest developments in  immuno-oncology combinations for advanced RCC including management of disease-related complications or adverse events. After the meeting, download the associated slidesets for use in your clinic.

During the scheduled live simulcasts, the experts will address live and remote audience questions sent to them during the event.

Register Now!


Welcome and Introduction

Rationale and Overview of the Use of Immune Checkpoint Inhibitor Therapy in RCC

Patient Case Discussions:

  • Planning optimal first-line treatment for individual patients with advanced or metastatic RCC
  • Optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Management of adverse events associated with IO combinations for advanced RCC

Summary and Audience Question and Answer Session 


Date / Time
Event Details


Program Director
M. Dror Michaelson, MD, PhD

Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Program Director
Robert Motzer, MD

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Target Audience
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the rationale for combining immune checkpoint inhibitors with another immune checkpoint inhibitor or VEGFR TKIs for the treatment of RCC
  • Identify patients most likely to benefit from immune checkpoint inhibitor–based combination therapy based on risk and biomarker assessment, along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.0 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: Will be provided for each event.

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistant Continuing Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.